|
TargetMol
amg510 Amg510, supplied by TargetMol, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/amg510/AMG-510/pm41326795-187-0-29 Average 95 stars, based on 1 article reviews
amg510 - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
MedChemExpress
amg510 ![]() Amg510, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/amg510/Sotorasib/pmc13223805-245-0-3 Average 96 stars, based on 1 article reviews
amg510 - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
|
Amgen
amg510 ![]() Amg510, supplied by Amgen, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/amg510/510+amg/us12552813-18-2-4 Average 86 stars, based on 1 article reviews
amg510 - by Bioz Stars,
2026-11
86/100 stars
|
Buy from Supplier |
|
Selleck Chemicals
amg510 ![]() Amg510, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/amg510/Sotorasib/pmc12682140-46-0-2 Average 94 stars, based on 1 article reviews
amg510 - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
Journal: Translational Oncology
Article Title: Sotorasib combined with 3-methyladenine for the treatment of KRAS G12C-mutant pancreatic cancer and its underlying mechanisms
doi: 10.1016/j.tranon.2026.102821
Figure Lengend Snippet: AMG510 suppresses the proliferation of KRAS G12C-mutant cells and induces cell cycle arrest . (A) Sanger sequencing confirmed that the pancreatic cancer cell line MiaPaCa-2 and the non-small cell lung cancer cell line H358 both harbor the KRAS codon 12 c.34G>T (p.G12C) mutation. (B) Dose–response curves and corresponding IC₅₀ values were determined using a CCK-8 assay after the treatment of MiaPaCa-2 and H358 cells with increasing concentrations of AMG510 for 48 h and 72 h. (C) Colony formation assays were performed to evaluate the effect of AMG510 on the clonogenic potential of MiaPaCa-2 and H358 cells. (D) Flow cytometry analysis of the cell cycle distribution of MiaPaCa-2 and H358 cells following treatment with varying concentrations of AMG510. (E) western blot analysis of the levels of cell cycle-related proteins (CDK2, Cyclin E, and Cyclin D3) in MiaPaCa-2 and H358 cells treated with the indicated concentrations of AMG510. β-Actin was used as a loading control. (F) Sanger sequencing validation revealed that PANC-1 cells carry the KRAS codon 12 c.35G>A (p.G12D) mutation. (G) CCK-8 assays were performed to evaluate the viability of PANC-1 cells at 48 h and 72 h after treatment with different concentrations of AMG510. (H) Colony formation assays were performed to assess the effects of different concentrations of AMG510 on the clonogenic capacity of PANC-1 cells. * P < 0.05; ⁎⁎ P < 0.01; ⁎⁎⁎ P < 0.001; and ⁎⁎⁎⁎ P < 0.0001.
Article Snippet:
Techniques: Mutagenesis, Sequencing, CCK-8 Assay, Flow Cytometry, Western Blot, Control, Biomarker Discovery
Journal: Translational Oncology
Article Title: Sotorasib combined with 3-methyladenine for the treatment of KRAS G12C-mutant pancreatic cancer and its underlying mechanisms
doi: 10.1016/j.tranon.2026.102821
Figure Lengend Snippet: AMG510 promotes apoptosis and induces mitochondrial dysfunction in KRAS G12C-mutant pancreatic cancer cells . (A) MiaPaCa‑2 and H358 cells were treated with the indicated concentrations of AMG510 for 48 h. Early and late apoptotic cells were quantified by flow cytometry using Annexin V‑FITC/PI staining. (B) western blot analysis of the levels of apoptosis‑related proteins (Bax, Bcl‑2, and cleaved PARP) in MiaPaCa-2 and H358 cells following treatment with different concentrations of AMG510. β‑Actin was used as a loading control. (C) PANC-1 cells were treated with the indicated concentrations of AMG510 for 48 h. Early and late apoptotic cells were quantified by flow cytometry using Annexin V-FITC/PI staining. (D) The mitochondrial membrane potential was evaluated in MiaPaCa-2 cells using a JC‑1 fluorescent probe and flow cytometry after 48 h of treatment with the indicated concentrations of AMG510. (E) Intracellular ROS levels were measured by flow cytometry using a DCFH-DA fluorescent probe following treatment with various concentrations of AMG510. The mean fluorescence intensity was quantified. (F) Fluorescence microscopy was performed to visualize ROS accumulation in MiaPaCa-2 cells treated with different concentrations of AMG510. The fluorescence intensity was quantified. * P < 0.05; ⁎⁎ P < 0.01; ⁎⁎⁎ P < 0.001; and ⁎⁎⁎⁎ P < 0.0001.
Article Snippet:
Techniques: Mutagenesis, Flow Cytometry, Staining, Western Blot, Control, Membrane, Fluorescence, Microscopy
Journal: Translational Oncology
Article Title: Sotorasib combined with 3-methyladenine for the treatment of KRAS G12C-mutant pancreatic cancer and its underlying mechanisms
doi: 10.1016/j.tranon.2026.102821
Figure Lengend Snippet: AMG510 effectively suppresses the growth of subcutaneous and orthotopic KRAS G12C-mutant pancreatic tumors in vivo . (A) Twelve mice were randomly assigned to two groups (n = 6 mice per group): control (DMSO) and AMG510 (10% AMG510 + 90% corn oil; 30 mg/kg/day). Representative images of the tumors after 21 consecutive days of oral gavage of DMSO or AMG510. (B) At the end of treatment, subcutaneous tumor weights were measured and compared between groups. (C) Body weights were monitored during the treatment period and compared between groups. (D) Subcutaneous tumor volumes were measured during the treatment period and compared between groups. (E) H&E staining and immunohistochemistry were performed on subcutaneous tumor samples to evaluate the levels of Ki-67, cleaved caspase-3, and LC3B. (F) At the end of treatment, the effects of AMG510 on complete blood counts and hepatic/renal function were assessed. (G) At the end of treatment, H&E staining was performed to evaluate histopathological changes in the heart, liver, spleen, lungs, and kidneys. (H) Ten mice were randomly assigned to one of two groups (n = 5 mice per group): control (DMSO) or AMG510 (10% AMG510 + 90% corn oil; 30 mg/kg/day). Representative images of orthotopic pancreatic tumors after 21 consecutive days of oral gavage of DMSO or AMG510. (I) Body weights were monitored during the treatment period and compared between groups. (J) At the end of treatment, orthotopic tumor weights were measured and compared between groups. (K) H&E staining and immunohistochemistry were performed on orthotopic tumor specimens to evaluate the levels of Ki-67, cleaved caspase-3, and LC3B. (L) At the end of treatment, the effects of AMG510 on complete blood counts and hepatic/renal function were assessed. (M) At the end of treatment, H&E staining was performed to evaluate histopathological changes in the heart, liver, spleen, lungs, and kidneys. * P < 0.05; ⁎⁎ P < 0.01; ⁎⁎⁎ P < 0.001; and ⁎⁎⁎⁎ P < 0.0001.
Article Snippet:
Techniques: Mutagenesis, In Vivo, Control, Staining, Immunohistochemistry
Journal: Translational Oncology
Article Title: Sotorasib combined with 3-methyladenine for the treatment of KRAS G12C-mutant pancreatic cancer and its underlying mechanisms
doi: 10.1016/j.tranon.2026.102821
Figure Lengend Snippet: AMG510 induces autophagosome accumulation in KRAS G12C-mutant cancer cells . (A) Transcriptomic profiling indicated differentially expressed genes in MiaPaCa-2 cells following treatment with 100 nM AMG510. (B) The Gene Ontology (GO) enrichment analysis revealed the significant enrichment of macroautophagy. (C) Transmission electron microscopy (TEM) was used to visualize autophagosomes in MiaPaCa-2 and H358 cells after 24 h of treatment with 100 nM AMG510. Red arrows indicate autophagosomes. (D) western blot analysis of LC3B-I, LC3B-II and p62 levels in MiaPaCa-2 and H358 cells treated with the indicated concentrations of AMG510; the LC3B-II/LC3B-I ratio was quantified. (E) MiaPaCa-2 and H358 cells were treated with DMSO, 100 nM AMG510, 10 μM chloroquine (CQ), or AMG510 (100 nM) plus CQ (10 μM) for 24 h. LC3B-I, LC3B-II and p62 expression were analyzed using western blotting, and the LC3B-II/LC3B-I ratio was calculated. (F) Under the same conditions, the levels of early autophagy-related proteins, including Beclin-1, p-mTOR and mTOR, in MiaPaCa-2 and H358 cells were evaluated by western blotting. ⁎ P < 0.05; ⁎⁎ P < 0.01; ⁎⁎⁎ P < 0.001; and ⁎⁎⁎⁎ P < 0.0001.
Article Snippet:
Techniques: Mutagenesis, Transmission Assay, Electron Microscopy, Western Blot, Expressing
Journal: Translational Oncology
Article Title: Sotorasib combined with 3-methyladenine for the treatment of KRAS G12C-mutant pancreatic cancer and its underlying mechanisms
doi: 10.1016/j.tranon.2026.102821
Figure Lengend Snippet: AMG510 induces early-stage autophagy in KRAS G12C-mutant cells without blocking autophagic flux . (A) MiaPaCa-2 and H358 cells were treated with DMSO, 100 nM AMG510, 10 μM CQ, or a combination of AMG510 (100 nM) and CQ (10 μM) for 24 h. Intracellular LC3B expression was assessed by performing immunofluorescence staining. (B) Quantification of the number of LC3B puncta per cell under the indicated treatment conditions. (C) MiaPaCa-2 cells were transduced with an mRFP-GFP-LC3 adenoviral vector and treated with DMSO, 100 nM AMG510, 10 μM CQ, or a combination of AMG510 (100 nM) and CQ (10 μM) for 24 h. Autophagic flux was evaluated by fluorescence microscopy. (D) H358 cells were transduced with an mRFP-GFP-LC3 adenoviral vector and treated with DMSO, 100 nM AMG510, 10 μM CQ, or a combination of AMG510 (100 nM) and CQ (10 μM) for 24 h. Autophagic flux was evaluated by fluorescence microscopy. * P < 0.05; ⁎⁎ P < 0.01; ⁎⁎⁎ P < 0.001; and ⁎⁎⁎⁎ P < 0.0001.
Article Snippet:
Techniques: Mutagenesis, Blocking Assay, Expressing, Immunofluorescence, Staining, Transduction, Plasmid Preparation, Fluorescence, Microscopy
Journal: Translational Oncology
Article Title: Sotorasib combined with 3-methyladenine for the treatment of KRAS G12C-mutant pancreatic cancer and its underlying mechanisms
doi: 10.1016/j.tranon.2026.102821
Figure Lengend Snippet: Effects of AMG510 and 3-MA on autophagy, proliferation, migration and apoptosis in KRAS G12C-mutant cells . (A) MiaPaCa-2 and H358 cells were treated with DMSO, 100 nM AMG510, 1 mM 3-MA, or a combination of AMG510 (100 nM) and 3-MA (1 mM). The expression of LC3B-I, LC3B-II and p62 was analyzed using western blotting, and the LC3B-II/LC3B-I ratio was calculated. (B) The viability of MiaPaCa-2 and H358 cells was assessed by performing a CCK-8 assay after 48 h of treatment with various concentrations of AMG510, either alone or in combination with 1 mM 3-MA. (C) MiaPaCa-2 cells were treated with DMSO, 100 nM AMG510, 1 mM 3-MA, or a combination of AMG510 (100 nM) and 3-MA (1 mM) for 14 days. Colony formation assays were performed to evaluate the clonogenic capacity of cells under each condition. (D) MiaPaCa-2 cells were subjected to the same treatment conditions for 72 h, and wound-healing assays were conducted to evaluate relative cell migration. (E) The apoptosis of MiaPaCa-2 cells was assessed using Annexin V-FITC/PI double staining and flow cytometry following 72 h of treatment with DMSO, 100 nM AMG510, 1 mM 3-MA, or the combination of AMG510 (100 nM) and 3-MA (1 mM). * P < 0.05; ⁎⁎ P < 0.01; ⁎⁎⁎ P < 0.001; and ⁎⁎⁎⁎ P < 0.0001.
Article Snippet:
Techniques: Migration, Mutagenesis, Expressing, Western Blot, CCK-8 Assay, Double Staining, Flow Cytometry
Journal: Translational Oncology
Article Title: Sotorasib combined with 3-methyladenine for the treatment of KRAS G12C-mutant pancreatic cancer and its underlying mechanisms
doi: 10.1016/j.tranon.2026.102821
Figure Lengend Snippet: Treatment with the combination of AMG510 and 3-MA further suppressed the growth of subcutaneous KRAS G12C-mutant pancreatic tumors in nude mice . (A) Twenty nude mice were randomly assigned to the following four groups (n = 5 mice per group): control (DMSO), AMG510 (10% AMG510 + 90% corn oil; 30 mg/kg/day), 3-MA (25 mg/kg/day), and AMG510 + 3-MA. Representative images of subcutaneous xenograft tumors after 21 consecutive days of treatment. (B) The tumor volumes were measured during the treatment period and compared among the groups. (C) Body weights were monitored during the treatment period and compared among groups. (D) At the end of treatment, subcutaneous tumor weights were measured and compared among the groups. (E) H&E staining and immunohistochemistry were performed on subcutaneous tumor samples to evaluate the levels of Ki-67, cleaved caspase-3, and LC3B. (F) Sanger sequencing of DNA from subcutaneous tumor specimens. (G) Sanger sequencing of cDNA derived from RNA extracted from subcutaneous tumor samples. * P < 0.05; ⁎⁎ P < 0.01; ⁎⁎⁎ P < 0.001; and ⁎⁎⁎⁎ P < 0.0001.
Article Snippet:
Techniques: Mutagenesis, Control, Staining, Immunohistochemistry, Sequencing, Derivative Assay
Journal: iScience
Article Title: Proteomics- and BRET- screens identify SPRY2 as a Ras effector that impacts its membrane organization
doi: 10.1016/j.isci.2025.113974
Figure Lengend Snippet: K-RasG12V engagement with SPRY2 is sensitive to lipidation inhibitors (A) Confocal imaging shows that the plasma membrane localization of mNG-tagged SPRY2 in HEK cells is sensitive to lipidation inhibitors mevastatin (Mev) and/or 2-bromopalmitate (2-BP). Scale bars = 20 μm (B–D) Effect of mevastatin (Mev) and/or 2-bromopalmitate (2-BP) on interaction-BRET of nL-K-RasG12V with mNG-SPRY2 (B), mNG-N-SPRY2 (C) or mNG-C-SPRY2 (D) in HEK cells (donor:acceptor plasmid ratio = 1:8). Plotted are means ± SEM from N = 5 independent biological repeats analyzed using Welch's t test (B–D). (E) Dose-dependent disruption of nL-K-RasG12C/mNG-SPRY2 BRET-interaction after treatment with G12Ci AMG510 in HEK cells (donor:acceptor plasmid ratio = 1:40). Plotted are means ± SEM from N = 3–9 independent biological repeats. (F) Dose-dependent effect of SNAP-tagged SPRY2 or N-SPRY2 expression on nL-K-RasG12V/mNG-C-Raf-RBD BRET in HEK cells (donor:acceptor plasmid ratio = 1:8). Plotted are means ± SEM from N = 4 independent biological repeats with values at highest modulator concentration compared using Welch's t test. Dashed line indicates the response to 5 μM mevastatin (Mev) treatment, indicating full plasma membrane displacement. See also .
Article Snippet:
Techniques: Imaging, Clinical Proteomics, Membrane, Plasmid Preparation, Disruption, Expressing, Concentration Assay